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Abstract
The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in 
multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we 
demonstrated in healthy individuals (n = 20) that the CD19 − CD81 expression axis identifies 
three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, 
immunoglobulin-production, and phenotype, consistent with progressively increased 
differentiation from CD19+CD81+ into CD19 − CD81+ and CD19 − CD81 − BMPCs. 
Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal 
BMPC counterparts, 59% had fully differentiated (CD19 − CD81 −) clones, 38% intermediate-
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differentiated (CD19 − CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter 
patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker 
for progression-free (HR: 1.7; P = 0.005) and overall survival (HR: 2.1; P = 0.006). Longitudinal 
comparison of diagnostic vs minimal-residual-disease samples (n = 40) unraveled that in 20% of 
patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We 
also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs 
retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show 
distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we 
shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated 
PCs have dismal survival, which might be related to higher chemoresistant potential plus different 
molecular and genomic profiles.
Introduction
Multiparameter flow cytometry (MFC) is currently considered a sensitive co-adjuvant test in 
the diagnostic screening of patients with multiple myeloma (MM) to demonstrate bone 
marrow (BM) clonality.1 Tumour plasma cells (PCs) from virtually all MM patients show 
phenotypic aberrancies that allow for clear distinction between these and normal PCs;2 
furthermore, the expression levels of some antigens are significantly associated with 
differences in outcome.3–7 One example is CD19, whose expression has been found in 5–
10% of MM cases and correlated with inferior survival;3 however, the biological explanation 
behind such correlation remains unknown. Recently, we showed that the expression of CD81 
in clonal PCs is also an independent prognostic factor in MM,4 but similarly to CD19, there 
is no knowledge on the biologic significance of CD81 expression in the surface of clonal 
PCs.
Normal PC differentiation is characterized by the acquisition of secretory capacity, cell-
cycle exit and changes in both surface phenotype and gene expression.8 Accordingly, CD19, 
which is a co-receptor of the B-cell receptor and is solely regulated by PAX5, becomes lost 
in a subset of normal BMPCs after PAX5 down-regulation during B-cell into PC 
differentiation.9,10 After the initial observation that CD19 expression was decreased in 
mature PCs generated in vitro,11 most recent analyses suggested that CD19−CD38hiCD138+ 
PCs share similarities with murine long-lived PCs and could represent their human 
counterpart.12,13 Since CD19 expression requires CD81,14 a tetraspanin widely expressed 
at all stages of the B-cell lineage,4,15 it could be hypothesized that both markers might 
contribute to identify unique PC subsets during the transition from less- into more-
differentiated BMPCs. In such cases, further investigations in MM would be warranted to 
unravel whether clonal PCs follow a similar pattern of normal PC differentiation according 
to CD19 − CD81 expression levels, and to determine the clinical sequelae of myeloma PCs’ 
differentiation stage.
Here, we started by showing that the combined expression of CD19 and CD81 identified 
three unique BMPC subsets in healthy individuals with distinct functional and phenotypic 
features, consistent with progressively increased differentiation from CD19+CD81+ into 
CD19−CD81+ and CD19−CD81− normal BMPCs. Subsequently, we demonstrated that 
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myeloma PCs fit into such a model of normal BMPC differentiation, and that patients with 
less-differentiated clones had dismal survival. PC differentiation is also related to therapy-
induced selective pressure, through which less-differentiated PCs subclones become 
enriched from diagnosis into minimal residual disease (MRD) stages in a subset of MM 
patients. Most interestingly, less-differentiated PCs maintain the expression of genes related 
to preceding B-cell stages, and show different mutation profiles as compared to fully 
differentiated PC subclones within individual MM patients.
Materials and Methods
Patients, controls and samples
A total of 225 elderly, transplant-ineligible patients with newly diagnosed symptomatic MM 
staged according to the International Myeloma Working Group criteria16 were prospectively 
studied after inclusion in the PETHEMA/GEM2010MAS65 trial (NCT01237249). In all 
cases, BM aspirates were collected at diagnosis and in 40 out of the 225 patients, also after 
induction therapy for preplanned MRD monitoring. BM aspirates were additionally taken 
from 20 healthy individuals (median age: 46 years; range: 19–64 years) to study the 
functional and phenotypic characteristics of normal PCs. All samples were collected after 
informed consent was given by each individual, according to the local ethical committees 
and the Helsinki Declaration.
Multidimensional flow cytometry (MFC) immunophenotyping
Approximately 200 μl of ethylenediaminetetraacetic acid-anticoagulated BM aspirated 
samples from newly diagnosed MM patients were immunophenotyped using two different 
eight-colour combinations of monoclonal antibodies (MoAb) and a direct 
immunofluorescence stain-and-then-lyse technique – (Pacific Blue (PacB)/Pacific Orange 
(PacO)/fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/peridinin chlorophyll protein-
cyanin 5.5 (PerCP-Cy5.5)/PE-cyanin 7 (PE-Cy7)/allophycocyanin (APC)/APCH7): (i) 
CD45/CD138/CD38/CD56/β2microglobulin/CD27/CD19/cyKappa/cyLambda; (ii) CD45/
CD138/CD38/CD28/CD27/CD19/CD117/CD81 following the EuroFlow guidelines17 to 
identify clonal PCs, and characterize their pattern of expression for CD19 and CD81. 
Patients with no reactivity for CD19 and < 10% CD81+ clonal PCs were classified as CD19-
CD81-, whereas those cases with < 50% CD19+ clonal PCs but CD81 expression (≥10%) 
were classified as CD19-CD81+; all remaining patients showing ≥ 50% CD19+ clonal PCs 
were classified as CD19+CD81+ (all of them were positive for CD81). After induction 
therapy, a single eight-colour MoAb combination (PacB/PacO/FITC/PE/PerCP-Cy5.5/PE-
Cy7/APC/APCH7) with CD45/CD138/CD38/CD56/CD27/CD19/CD117/CD81 was used to 
monitor MRD, and whenever persistent MRD was detected, the percentage of CD19+ and/or 
CD81+ clonal PCs was determined to compare, at the individual-patient-level, with that 
found at diagnosis. The same eight-colour MoAb combination was used to characterize the 
BMPC compartment of the 20 healthy individuals. In five out of the former 20 cases, an 
additional eight-colour MoAb combination (BV421/BV510/FITC/PE/PerCP-Cy5.5/PE-
Cy7/APC/APCH7) with CD138/CD27/cyIgM+cyIgA/cyIgA+cyIgG/CD38/CD19/cyKappa/
CD81 was stained to quantify the cytoplasmic (cy) immunoglobulin (Ig) heavy chain 
distribution in different PC subsets according to CD19 − CD81 expression. Data acquisition 
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was performed for approximately 106 leukocytes/tube in an FACSCantoII flow cytometer 
(Becton Dickinson – BD – San Jose, CA, USA) using the FACSDiva 6.1 software (BD). 
Data analysis was performed using the Infinicyt software (Cytognos SL, Salamanca, Spain).
Quantitation of replication history
B-lymphocyte precursors, transitional, naive and memory B-cells, CD19+ and CD19− PCs 
were FACS-sorted (FACSAria II, BD; purity ≥ 97%) from BM samples of healthy 
individuals (n = 5), according to their respective phenotypic characteristics as described 
elsewhere.18–20 The replication history of B-lymphocytes and PCs was determined using 
the κ-deleting recombination excision circle assay, which is based on the quantification of 
coding joints and signal joints of an Ig-deleting rearrangement (intron RSS-Kde) by real-
time quantitative PCR.20 Primers and probes were designed to specifically amplify the 
intronRSS-Kde rearrangements (coding joint) and the corresponding signal joint using 
TaqMan-based real-time quantitative PCR from DNA isolated from FACS-sorted cell 
subsets.20 The real-time quantitative PCR mixture of 25 μl contained TaqMan Universal 
MasterMix (Applied Biosystems, Waltham, MA, USA), 900 nM of each primer, 100 nM of 
each FAM-TAMRA-labelled probe, 50 ng of DNA and 0.4ng BSA, and was run on the 
ABIPRISM 7700 sequence detection system (Applied Biosystems).20
Cell cycle analyses
The proliferation index of different normal PC subsets according to CD19 − CD81 
expression was analysed in BM samples from five healthy individuals using five-colour 
staining for nuclear DNA and four cell surface antigens (CD19–PacB/CD45–PacO/CD38–
FITC/CD81–PE) as described elsewhere.21
Single-cell multidimensional phenotyping
Bone marrow aspirates from healthy individuals (n = 10) were immunophenotyped using 
four different eight-colour combinations of MoAb: (PacB, PacO, FITC, PE, PerCP-Cy5.5, 
PE-Cy7, APC, alexafluor 700 (AF700)): (i) CD29, CD45, CD11a, β7, CD79b, CD49d, 
CD19, CD38; (ii) CD11c, CD45, CD41a, CD49e, CD33, CD117, CD19, CD38; (iii) CD20, 
CD45, CD81, CD54, CD138, CD56, CD19, CD38; and (iv) HLA-DR, CD45, CD44, 
CXCR4, CD27, CD28, CD19, CD38. The expression of all 23 phenotypic markers was 
analysed at the single PC-level and compared between the CD19+CD81+, CD19−CD81+ and 
CD19−CD81− subsets, using the merge and calculation functions of the Infinicyt software as 
described elsewhere.22–24
Fluorescence-in-situ-hybridization (FISH) and deep-targeted sequencing
FISH was performed at diagnosis on immunomagnetic-enriched PCs from 169 out of the 
225 cases with available phenotypic data. DNA from two PC clones FACS-purified 
according to their differentiation status from six newly diagnosed MM patients was analysed 
including the corresponding germline samples. DNA was extracted from cells using AllPrep 
DNA/RNA Micro Kit, Qiagen (Hilden, Germany). Targeted gene sequencing was performed 
using 20 ng of input DNA and applying the MM Mutation Panel Version 2.0 (M3P 2.0). 
Targeted panel consists of 1271 amplicons from 77 genes commonly mutated in MM. 
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Enriched templates were sequenced using semiconductor technology (Ion Proton, Life 
Technologies, Waltham, MA, USA) and analysed with Ion Reporter Software v4.4 (Life 
Technologies). A median of 1700x depth coverage was obtained. Mutation calls were 
considered positive when called by ≥ 5% variant reads, with a minimum depth coverage of 
10 reads.
Gene expression profiling (GEP)
A total of 71 newly diagnosed MM patients screened at the University of Arkansas for 
Medical Sciences and with simultaneously available information on CD19 and CD81 
immunophenotypic patterns of expression and GEP were included in this analysis. An 
aliquot of BM aspirate was collected to isolate CD138+ PCs with immunomagnetic bead 
selection (autoMACS; Miltenyi Biotec, Bergisch Gladbach, Germany), as described 
elsewhere.25 Purity of PC was monitored by flow cytometry and was ≥ 85%. Total RNA 
was used to measure GEP with Affymetrix U133 Plus 2.0 microarrays. Differentially 
expressed genes between classes were identified using the Significant Analysis of 
Microarrays algorithm. Analyses were performed using BRB-ArrayTools (version 4.4.1) 
developed by Dr Richard Simon and the BRB-ArrayTools Development Team, available at 
http://linus.nci.nih.gov/BRB-ArrayTools.html.
DNA methylation studies
We used the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) for bisulfite 
conversion of 500 ng genomic DNA. Bisulfite-converted DNA was hybridized onto the 
HumanMethylation 450 K BeadChip kit (Illumina, San Diego, CA, USA). Data from the 
450 k Human Methylation Array were analysed as described previously.26
Statistical analysis
Correlation studies between PC subset distribution and age were performed using the 
Pearson test. The Wilcoxon signed rank test was used to evaluate the statistical significance 
of the percentage of each PC subset in the distinct phases of the cell cycle, as well as for the 
replication history of each PC subset. Conversely, the Friedman test was used to compare the 
distribution according to the heavy-chain Ig isotype across the different PC subsets. The 
Mann–Whitney U and the Kruskal–Wallis tests were used to estimate the statistical 
significance of differences observed between two or more groups, respectively. Survival was 
analysed by the Kaplan–Meier method, and differences between curves were tested for 
statistical significance with the two-sided log-rank test. Progression-free survival (PFS) was 
defined as the time from diagnosis to disease progression or death from any cause, and 
overall survival (OS) as time from diagnosis to death from any cause. A multivariate Cox 
proportional hazard model was developed to explore the independent value of significant 
variables on the univariate analysis, and variables were retained in the model for levels of 
significance P < 0.05.The SPSS software (version 20.0; IBM, Armonk, NY, USA) was used 
for all statistical tests.
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Combined expression of CD19 and CD81 identifies three unique normal BM PC subsets
We first determined the distribution of the CD19+CD81+, CD19−CD81+ and CD19−CD81− 
subsets within total BMPCs from healthy individuals; overall, the CD19+CD81+ subset 
accounted for the majority of PCs (median of 79% within the BMPC compartment), 
followed by the CD19−CD81+ and CD19−CD81− subsets (14 and 5%, respectively). 
However, when we compared the distribution of each subset within the BMPC compartment 
across different age decades, we noted that while CD19−CD81+ and CD19−CD81− PCs were 
almost absent among healthy individuals aged 10–20 years, their frequency progressively 
increased from younger to older individuals (Figure 1a). Accordingly, there was a significant 
(P ⩽ 0.006) correlation between age and the distribution of the CD19+CD81+, CD19−CD81+ 
and CD19−CD81− subsets (Figure 1a), suggesting that CD19+CD81+ normal BMPCs appear 
earlier in the development of antibody responses, whereas CD19−CD81+ and CD19−CD81− 
PCs accumulate in the BM later in life. Since during PC differentiation acquisition of 
secretory capacity is accompanied by progressive cell cycling exit, we subsequently 
explored the distribution of the CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets 
within G0/G1 and S-phase/G2M normal BMPCs. As expected, the majority of BM PCs were 
in G0G1 (data not shown), but while the relative distribution of all three CD19+CD81+, 
CD19−CD81+ and CD19−CD81− subsets in G0G1 was inside the normal ranges described 
above, there were virtually no CD19−CD81− PCs in S-phase/G2M (Figure 1b; P = 0.03). 
Thus, CD19−CD81− normal PCs were not only enriched in the BM of elderly healthy 
individuals, but also showed virtually no proliferation, suggesting that among CD19− PCs, 
those lacking CD81 could be more differentiated than CD19−CD81+ BMPCs. Additional 
analysis was performed to assess the replication history of CD19+CD81+ and total CD19− 
BMPCs, since it was not possible to purify sufficient cells numbers for the κ-deleting 
recombination excision circle assay from CD19−CD81+ and CD19−CD81− BMPCs 
separately (Figure 1c); that notwithstanding, we confirmed that PCs have a superior median 
number of cell cycles compared to B-lymphocytes (P = 0.04), but also showed that within 
the BMPC compartment, the median number of cell cycles in CD19− PCs was slightly 
superior to that of CD19+ PCs (P = 0.08). Additionally, there was a trend (P = 0.07) for an 
altered distribution of Ig heavy-chain isotypes between PC subsets according to their CD19 
− CD81 expression, with progressively decreasing frequencies of IgA+ PCs counterbalanced 
with increasing numbers of IgG+ PCs along the respective CD19+CD81+, CD19−CD81+ and 
CD19−CD81− BMPC subsets (Figure 1d). Further phenotypic differences were observed 
after single-cell analysis of 21 markers within the CD19 − CD81 phenotypic pathway, with 
decreasing mean fluorescence intensity of CD27, CD38, CD44 and CD54 combined with 
progressively increased expression of CD28 and CD56 being observed along the 
CD19+CD81+, CD19−CD81+ and CD19−CD81− BMPC subsets (Figure 1e). Overall, our 
results indicate that the combined CD19 − CD81 pattern of expression identifies three 
BMPC subsets with singular functional and phenotypic characteristics, consistent with an 
accumulation of long-lived, less active and fully differentiated PCs from the CD19+CD81+ 
and CD19−CD81+ into the CD19−CD81− BMPC subsets.
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Clinical sequelae of the differentiation stage of myeloma PC clones
After demonstrating the existence of three well-defined normal BMPC subsets with distinct 
differentiation, we sought to determine how myeloma PC clones fit in such a model of 
normal BMPC differentiation. Upon specific analysis of the CD19 − CD81 pattern of 
expression in clonal PCs from 225 newly diagnosed MM patients, we found that more than 
half (132/225; 59%) had clonal PCs that phenotypically matched the fully differentiated 
normal PC counterpart (that is: CD19−CD81−); conversely, 86 out of the 225 patients (38%) 
displayed intermediate-differentiated myeloma PCs (that is: CD19−CD81+), whereas only 
seven cases (3%) showed clonal PCs for which the normal counterpart would correspond to 
the less-differentiated BMPC subset (that is: CD19+CD81+). Interestingly, patients with less- 
and intermediately differentiated clonal PCs had a different phenotypic profile vs cases with 
a fully differentiated PC phenotype (Table 1), with significantly less frequent CD28+ and 
CD117+ expression; conversely, CD45 positivity was more frequent among patients with 
less-differentiated PC clones (Table 1). Furthermore, we noted a trend (P = 0.07) for higher 
frequencies of cytogenetic abnormalities (that is: t(IGH), +1q, del(13q), and/or del(17p)) 
from patients with less-into intermediate- and fully differentiated PCs (Table 2); in fact, 
cases with less-differentiated clones only showed +1q, and no IGH translocations nor 
del(13q) nor del(17p). Patients with less-and intermediately differentiated clonal PCs 
achieved lower MRD-negative rates as compared to cases with a more mature PC phenotype 
(25 and 20 vs 40%; P = 0.03). Upon investigating if the differentiation stage of myeloma PC 
clones influenced patients’ prognosis, we noted that progression-free survival and overall 
survival of cases in less- and intermediate-differentiation stages was significantly inferior as 
compared to patients with fully differentiated CD19−CD81− myeloma PC clones (Figures 2a 
and b). The treatment arm had no impact in patients’ outcomes according to PC 
differentiation (data not shown). Multivariate analysis of baseline prognostic factors for 
survival including the differentiation stage of clonal PCs plus patients’ age, ISS and FISH 
cytogenetics showed that the best combination of independent predictive parameters for 
progression-free survival and overall survival were PC differentiation and FISH cytogenetics 
(Table 3). Accordingly, the differentiation stage of clonal PCs continued to be prognostically 
relevant for progression-free survival and overall survival when the analysis was restricted to 
cytogenetically defined standard-risk cases (Figures 2c and d), suggesting that the presence 
of less-differentiated myeloma PC clones identifies a subgroup of patients with more 
aggressive disease despite standard-risk cytogenetic profiles.
Less-differentiated PC clones may become predominant at the MRD stage
Since the differentiation stage of clonal PCs at baseline was intrinsically related to patients’ 
response to therapy and survival, we subsequently evaluated the in vivo chemoresistant 
profile of different myeloma PC clones according to their differentiation stage, by 
performing a longitudinal comparison of the CD19 − CD81 pattern of expression in clonal 
PCs at diagnosis (baseline) vs after treatment during MRD monitoring (the chemoresistant 
subclone) in 40 MM patients. Overall, we found that while the expression of CD19 remained 
mostly stable between baseline and MRD (Figure 3a), there was a significant increase in the 
percentage of CD81+ chemoresistant clonal PCs after therapy (mean of 31 vs 21% at 
baseline, P = 0.04). Accordingly, 30/40 (75%) patients displayed the same differentiation 
stage during baseline and MRD monitoring (16 corresponding to the fully differentiated PC 
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subset (that is: CD19−CD81−) and 14 to the intermediate stage (that is: CD19−CD81+)), 
whereas 10/40 (25%) patients showed clonal selection of PCs with altered differentiation 
upon therapy-induced selective pressure (Figure 3b). Namely, eight cases with fully 
differentiated phenotypes at diagnosis showed intermediate stage chemoresistant clonal PCs 
after therapy; conversely, the remaining two patients transitioned from a CD19−CD81+ into 
a CD19−CD81− phenotype (Figure 3b). These results demonstrate that in approximately 
one-fourth of MM patients there might be clonal selection upon therapy of PC subsets with a 
distinct differentiation stage to that observed in the majority of myeloma PCs at diagnosis; 
such clonal dynamics usually favour less-differentiated PC subclones.
Mutation profiles of intraclonal heterogeneity according to PC differentiation
Upon observing that in selected patients less-differentiated PC subclones became 
predominant under therapeutic pressure, we decided to investigate whether less- and fully 
differentiated PC subclones could eventually display different genomic profiles. In order to 
address this hypothesis, we investigated the presence of mutations in PC subclones sorted 
according to their differentiation stage within individual patients (n = 6), by using a 
comprehensive panel covering 77 genes. While one case had no detectable mutations among 
those tested in any of the FACS-purified CD19−CD81+ and CD19−CD81− PC subsets (#1; 
Figure 4a), the five remaining patients had detectable mutations and their pattern differed 
within PC subclones sorted according to their differentiation stage. Namely, in case#2 
CD19−CD81+ myeloma PCs displayed mutations in SP140 that were not present among 
more differentiated CD19−CD81− PCs. Similarly, patient#3 had a mutation in epidermal 
growth factor receptor among less-differentiated tumour cells while absent in intermediate- 
and fully differentiated clones. Patient#4 showed a mutation in DIS3 that was 
simultaneously present in CD19−CD81+ and CD19−CD81− myeloma PCs; however, 
intermediate-differentiated cells had an additional mutation in IKZF3. Cases #5 and #6 
showed the highest differences between the mutation profiles, with mutually exclusive 
mutations among intermediate- vs fully differentiated myeloma in both cases. Overall, these 
results suggest that tumour heterogeneity, dissected according to PC differentiation on 
phenotypic grounds, may uncover the presence of subclones with different mutation profiles.
GEP of MM patients according to the differentiation stage of myeloma PC clones
After demonstrating that myeloma PCs followed the same model of differentiation as 
observed in BMPCs from healthy individuals, and that such a model had a clear implication 
in patients’ survival, we decided to investigate if the differentiation stage of myeloma PC 
clones would underlie different mRNA expression. Our results showed that newly diagnosed 
MM patients with less-differentiated clonal PCs (that is: CD19+CD81+; n = 8) displayed 39 
deregulated genes as compared to cases with intermediate-differentiation (that is: 
CD19−CD81+; n = 33) (Supplementary Excel File 1). CD19 mRNA expression was 
consistent with that observed on phenotypic grounds and was down-regulated among 
CD19−CD81+ patients; most-interestingly, down-regulation of other B-cell related genes 
such as CD79A, MS4A1 (CD20) and PAX5 was also observed. PTPRCAP, which stabilizes 
the expression of CD45, the pre-B-lymphocyte 3 protein coding gene VPREB3, TNFSF8 
and CCND1 were also found to be down-regulated among CD19−CD81+ patients. Although 
no significantly deregulated genes were observed upon comparing patients with 
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CD19−CD81+ vs CD19−CD81− (n = 28) phenotypes, gene set enrichment analysis showed 
that patients with intermediate-differentiated CD19−CD81+ PCs had significantly up-
regulation of cell cycle, nucleotide excision repair and DNA replication pathways as 
compared to those with fully differentiated CD19−CD81− PCs, which is consistent with the 
higher proliferative potential of the former PC subset. Conversely, patients with fully 
differentiated PCs showed down-regulation of pathways related to protein processing in ER, 
among others (Supplementary Excel File 2). The comparison between patients with less- vs 
fully differentiated (that is: CD19+CD81+ vs CD19−CD81−) PCs showed up-regulation of 
FCRLB, MS4A1 (CD20), CTGF, BEND5 and CD81 in less-differentiated clones 
(Supplementary Excel File 1). Overall, these results confirm a correlation between the 
phenotype and the GEP of PCs, but also that phenotypically less-differentiated 
CD19+CD81+ myeloma clones retain higher expression of genes associated with preceding 
B-cell stages.
Discussion
In other hematological malignancies such as acute myeloid leukemia, it is current practice to 
classify blasts according to their differentiation stage, and the concept of cellular plasticity 
with more immature clones being typically enriched at the MRD and relapse stages has been 
recognized.27 In MM, it has recently been suggested that a progenitor organization exists 
within clonal PCs that recapitulates maturation stages between B-cells and PCs, and may 
contribute to in vitro chemoresistance.28 However, there is no accurate knowledge on the 
myeloma PC differentiation pathway, nor how these correlate with patients’ clinical 
behaviour; in fact, information on the correct identification of less- vs fully differentiated 
normal BMPCs is yet very limited.12,13 Here, we showed the existence of three well-
defined maturation stages in both normal and clonal BMPCs identified through the CD19 − 
CD81 expression axis, and that MM patients harbouring less-differentiated PCs have dismal 
survival. We also showed that the level of PC differentiation in MM could be related, at least 
in part, to different chemoresistant potential together with different molecular and genomic 
profiles.
The variable half-life of different serum antibodies (for example: in response to measles and 
mumps vs influenza viruses)29 is consistent with specific survival patterns among unique 
PC subsets, with long-lived PCs being responsible for maintaining such antibody titres for a 
life-span of several years or decades.30 Two recent studies have characterized CD19− 
normal PCs and concluded that these are specifically enriched in the BM and display unique 
morphological, transcriptomic and phenotypic features consistent with increased 
differentiation as compared to CD19+ PCs;12,13 accordingly, affinity for viral antigens to 
which healthy individuals had not been exposed for more than 40 years have been 
exclusively detected among CD19− BMPCs.12 Such observations open new research areas 
to further investigate the features of specific normal and pathological PC subsets according 
to their differentiation.12 Thus, reinforced by the recent confirmation31 of the regulatory 
role of CD81 over CD19 within the B-cell co-receptor,14,32–34 we decided to investigate if 
the CD19 − CD81 pattern of expression could help to further dissect unique PC 
differentiation subsets. Our results are consistent with those reported by Halliley et al.12 and 
Mei et al.13 and show that in healthy individuals, CD19− BMPCs are less proliferative and 
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are enriched in IgG secreting cells, as compared to the CD19+ subset. The notion that 
CD19− BMPCs are more differentiated than the positive subset was further confirmed in our 
study after demonstrating that the former have higher replication history. However, we also 
showed that CD19− BMPCs can be further dissected into CD19−CD81+ and CD19−CD81− 
subsets, and that the latter represent the most differentiated compartment among total 
BMPCs.
Longevity of PCs in BM is restricted by competition for niche space35 and in this 
competitive model, PC intrinsic features likely contribute to determine their life span by 
controlling PC function and niche affinity.11 Here, CD28 and CD56 expression was found 
to be progressively increased from less- CD19+CD81+ into more-differentiated 
CD19−CD81+ and CD19−CD81− BMPCs; accordingly, long-term humoral immunity has 
been reported to depend on the PC-intrinsic function of CD28 signalling down-stream of the 
CD28 Vav motif that regulates BLIMP1.36 CD56 is likely contributing to stronger PC 
adhesion to BM stromal niches. Most interestingly, pathological PCs in MM displayed a 
similar phenotypic behaviour as compared to normal PCs, and patients with fully 
differentiated clones also showed higher expression of CD28 and CD56, as well as CD38low. 
The fact that mature CD19−CD81− normal BMPCs are absent in infants aged 5–7 months13 
but progressively accumulate later in life as shown here, is also a remarkable coincidence 
with the fact that monoclonal gammopathy of undetermined significance and MM typically 
develop in the elderly, and that more than half of the patients (59%) display PC clones that 
phenotypically overlap with fully differentiated normal PCs. Since loss of CD19 and CD81 
expression was observed in both normal and tumour PC differentiation, we hypothesized 
that their regulation was under epigenetic grounds. Thus, we analysed DNA methylation 
levels around the CD81 gene (in its upstream CpG island shore region, CpG island, gene 
body region close to CpG island (Gene Body 1) and the rest of gene body (Gene Body 2)) in 
three MM cell lines with variable levels of CD81 expression (Figure 5). While no 
differences in DNA methylation in the CpG island shore and Gene Body 2 regions were 
observed, the methylation levels in the CpG island and Gene Body region 1 showed a clear 
correlation with CD81 expression, suggesting that these regions contain regulatory elements 
that control CD81 expression. Accordingly, methylation in the CpG island and CD81 
expression were inversely correlated. In contrast, levels of DNA methylation in the Gene 
Body region 1 were positively correlated with gene expression. This dual pattern of negative 
and positive association between gene expression and DNA methylation depending on the 
region analysed has been previously observed,37 and underlines that the function of DNA 
methylation is genomic context dependent.38
The notion that PCs represent the terminally differentiated end-stage of the B-cell lineage 
has likely contributed to a deficiency in knowledge about the levels of phenotypic plasticity 
and maturation of clonal PCs in MM.28,39 Here, we show that up to 41% of MM patients 
display at diagnosis PC clones corresponding to less-differentiated normal PC counterparts, 
including 3% corresponding to the more immature CD19+CD81+ subset. Most interestingly, 
the latter maintain high expression of genes typically related to mature B-cell stages such as 
PAX5, CD20, CD79b, VPREB3, TNFSF8 and CCND1 as revealed by comparing their GEP 
against that of PCs obtained from patients with intermediate- (CD19−CD81+) and fully 
differentiated phenotypes (CD19−CD81−). These results suggest that the proposed 
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phenotypic differentiation model of myeloma PCs is corroborated at the molecular level, 
similarly to what has been recently shown in normal BMPCs from healthy individuals.12 
Importantly, MM patients harbouring less-differentiated PC clones had dismal outcome with 
a median survival of approximately 1 year. Accordingly, the differentiation status of clonal 
PCs emerges as a new and independent prognostic marker in MM, complementary to 
patients’ cytogenetic profile. In fact, patients’ characterization according to PC 
differentiation status allowed the identification of a subset of cases with dismal survival 
albeit standard-risk cytogenetics. It should be noted that the small number of cases 
harbouring less-differentiated PC clones limits the robustness of the statistical comparison 
between groups (particularly regarding survival analyses), and these results should be 
reproduced in larger series of patients (for example: GEM2005MENOS65 and 
GEM2005MAS65 clinical trials; Supplementary Figure 1). That notwithstanding, the 
availability of multiple novel and effective drugs combined with the advent of high-
throughput (cellular and molecular) techniques, may help to identify small patient subgroups 
with a unique biology that could benefit from tailored treatment (for example: anti-CD19 
CAR T-cells40 for cases with less-differentiated myeloma PCs).
The identification of more immature cancer (stem) cells has been historically pursued to 
justify unexplainable relapses, particularly among patients achieving CR.41,42 However, 
relapses among MM patients in CR are now better understood and predicted with the advent 
of MRD monitoring, which have shown an intrinsic correlation between the persistence of 
residual clonal PCs after therapy (that is: MRD) and inferior survival.43–46 Here, we used a 
novel approach to understand ultra-chemoresistance by performing in individual patients 
longitudinal comparisons between clonal diversity according to PC differentiation at 
diagnosis vs MRD.22 Hence, we showed that therapeutic pressure may lead to in vivo 
selection of specific PC subsets, and that in approximately one-fourth of MM patients such 
clonal selection favoured less-differentiated PC subclones. Thus, further studies are 
warranted to establish a clear relationship between the extent of PC differentiation and their 
chemoresistant potential. On a different note, these results may also reflect previously 
unknown levels of cellular plasticity in vivo,47 by which PCs can transition from mature 
into more immature stages (and vice-versa) upon therapeutic pressure. The observations that 
CD81 expression is epigenetically regulated together with the lack of a clear pattern of 
accumulating mutations in FACS-purified immature vs mature PCs subclones from 
individual patients, would support such phenomenon of cellular plasticity. Thus, establishing 
the temporal acquisition of mutations and genetic abnormalities in less- vs more-
differentiated PC clones should be investigated in future studies. Interestingly, these findings 
also unravel that detailed characterization of the MRD PC compartment might be as 
informative as more conventional MRD quantitation to predict patients’ outcome (for 
example: survival of an MRD-positive patient displaying immature PC clones may be poorer 
than other MRD-positive cases).23,48
In summary, we shed new light into normal and tumour PC plasticity, with the identification 
of three well-defined differentiation subsets in both healthy individuals and MM patients, 
respectively. The demonstration that tumour PC differentiation might be related to unique 
chemoresistant, molecular and mutation profiles highlights its importance in the 
prognostication and monitoring of MM patients.
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Bone marrow (BM) normal plasma cell (PC) subsets according to the CD19 − CD81 
expression axis. (a) Age-related changes in the distribution of BM normal PC subsets. The 
percentage of the CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets within total BM 
PCs from each healthy donor (n = 20) was determined, and median values per subset for 
each age decade are represented by light, intermediate and dark blue areas, respectively. 
Linear regression between individuals’ age and the respective percentage for each PC subset 
is also shown. (b) Proliferative potential of the different BM normal PC subsets. The 
percentage of the CD19+CD81+ (light blue), CD19−CD81+ (intermediate blue) and 
CD19−CD81− (dark blue) subsets within total BM PCs from healthy donor (n = 5) in G0/G1 
and S-phase/G2M phases of the cell cycle is shown. (c) Quantification of the replication 
history of progressively maturing BM B cell and PC subsets from healthy individuals using 
κ-deleting recombination excision circles. The line in the middle and vertical lines 
correspond to the median value and both the 10th and 90th percentiles, respectively, for the 
ΔCT between the coding joint and the signal joint in FACS-sorted B-cell precursors, 
transitional, naïve and memory B-cells, CD19+ and CD19− PCs from BM samples of 
healthy individuals (n = 5). (d) Immunoglobulin (Ig) heavy chain isotype distribution of the 
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different BM normal PC subsets. After PC identification according to their bright CD38 and 
CD138 expression and unique scatter characteristics, cyIgG+ PCs were defined as those 
showing reactivity in the PE channel (cyIgA+cyIgG) but not in the FITC channel (cyIgM
+cyIgA), whereas cyIgA+ PCs were defined as those showing (diagonal) double-staining in 
the FITC+PE channels; cyIgM+ PCs were defined by reactivity in the FITC channel but not 
in PE. The percentage of cytoplasmic IgG, IgA and IgM is shown within the respective 
CD19+ CD81+, CD19−CD81+ and CD19−CD81− subsets. (e) Immunophenotypic protein 
expression profiles of the different BM normal PC subsets. Due to the existence of five 
parameters measured in common for each aliquot (CD38, CD45, CD19, forward light scatter 
– FSC and sideward light scatter – SSC), it was possible to define the PC compartment in 
each aliquot and fuse the different data files corresponding to the four different eight-colour 
MoAb combinations studied per sample into a single data file containing all information 
measured for that sample, using the merge function of the Infinicyt software. For any single 
PC in each eight-colour MoAb combination, this included data about those antigens that 
were measured directly on it and antigens that were not evaluated directly (‘missing values’) 
for that cell in the corresponding tube it was contained in. Then, the calculation function of 
the Infinicyt software was used to fill in the ‘missing values’, based on the ‘nearest 
neighbour’ statistical principle, defined by the unique position of individual PCs the 
multidimensional space created by the five common (backbone) parameters (FSC, SSC, 
CD38, CD45 and CD19). Ultimately, the expression of all 23 phenotypic markers could be 
analysed at the single PC level, and compared between PCs clustering into the specific 
CD19+CD81+, CD19−CD81+ and CD19−CD81− subsets. Markers differentially expressed 
between the CD19+CD81+ (light blue), CD19−CD81+ (intermediate blue) and CD19−CD81− 
(dark blue) subsets within BM normal PCs from healthy individuals (n = 10). Notched boxes 
represent the 25th and 75th percentile values of the amounts of antigen mean fluorescence 
intensity expression per BM PCs; the line in the middle and vertical lines correspond to the 
median value and both the 10th and 90th percentiles, respectively.
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Multiple myeloma (MM) patients’ survival according to the differentiation stage of 
myeloma PC clones. Panels a and b show progression-free survival (PFS) and overall 
survival (OS) for the overall series of MM patients (n = 225) grouped according to the 
differentiation stage of clonal plasma cells (PCs) at diagnosis: more-differentiated 
(CD19−CD81−), intermediate-differentiated (CD19−CD81+) and less-differentiated 
(CD19+CD81+). Patients’ treatment consisted of either nine identical induction cycles with 
bortezomib, melphalan, prednisone (VMP) followed by other nine cycles of lenalidomide 
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plus low-dose dexamethasone (Rd; n = 112), or alternating cycles of VMP and Rd for up to 
18 courses (n = 113). The median follow-up of the series was 3 years. Panels c and d show 
PFS and OS in patients with standard-risk cytogenetics (n = 154; all those cases without 
t(4;14), t(14;16) and/or del(17p13)).
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Therapeutic selection at the MRD stage of myeloma PC subclones defined according to their 
differentiation stage. (a) Correlation between the percentage of CD19 (black squares) and 
CD81 (open circles) positive plasma cells (PCs) within total baseline (x axis) vs MRD (y 
axis) clonal PCs in longitudinal bone marrow samples from 40 multiple myeloma (MM) 
patients analysed at diagnosis and after therapy. (b) Schema showing the frequency of 
patients following specific clonal dynamics according to the differentiation stage of 
myeloma PCs from diagnosis to the MRD stage. Representative bivariate dot plot 
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histograms illustrating the patterns of CD19 vs CD81 expression in clonal PCs at diagnostic 
(represented by lines corresponding to one and two SD) and at the MRD stage (red dots) 
corresponding to four out of the eight patients that evolved from baseline more differentiated 
(that is: CD19−CD81−) into intermediate-differentiated (that is: CD19−CD81+) 
chemoresistant PC clones after therapy, ordered from left to right, denoting high to low 
MRD levels, are also shown. Twelve out of the 30 patients displaying the same 
differentiation stage during baseline and MRD monitoring attained CR, three out of the eight 
cases with fully differentiated phenotypes at diagnosis showing intermediate stage 
chemoresistant clonal PCs after therapy attained CR, and so did one out of the two patients 
transitioned from a CD19−CD81+ into a CD19−CD81− phenotype.
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Distinct PC differentiation subsets within individual patients show different mutation 
profiles. Clonal plasma cells (PCs) corresponding to the intermediate- (CD19−CD81+) and 
more-differentiated (CD19−CD81−) subsets were FACS-sorted from patients #1, #2, #4, #5 
and #6 (a, b, d, e and f) for mutation analysis using a targeted-sequencing panel covering 77 
genes; in patient #3 (c), mutations were investigated in less-differentiated (CD19+CD81+) vs 
intermediate- (CD19−CD81+) and more-differentiated (CD19−CD81−) PC clones.
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The sequential CpGs measured by HumanMethylation450 BeadChip for the CD81 gene. We 
investigated the expression levels of CD19 and CD81 in a large panel of MM cell lines 
(RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3, MM1S, MM1R, MM144, U266, 
U266-DOX4, U266-LR7, SJR and MGG) and identified five cell lines positive for CD81 
(RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3) in the absence of CD19; all the others 
exhibited no expression for both CD19 and CD81 (data not shown). Afterward, under the 
hypothesis that loss of CD81 expression could be due to epigenetic regulation of the CD81 
gene, we investigated the DNA methylation profile of CD81 in the NCI-H929, JJN3 and 
U266 cell lines (the first two positive for CD81 and the third negative). Accordingly, we 
observed an inverse correlation between DNA methylation levels in the CpG island region of 
the CD81 gene and the protein (antigen) expression level of CD81 in the three MM cell 
lines. Interestingly, the DNA methylation levels in the CpG island region were also inversely 
correlated with the DNA methylation levels in the gene body region of CD81. These results 
indicate that an epigenetic mechanism of DNA methylation plays an important role in the 
regulation of CD81 expression. The mean of the DNA methylation levels of the CpGs 
located in the CpG island or gene body region of CD81 are also shown.
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Table 1
Phenotypic features of patients with less-differentiated (that is, CD19+CD81+), intermediate-differentiated 
(that is: CD19-CD81+) vs more-differentiated (that is, CD19-CD81-) plasma cell clones among newly 
diagnosed multiple myeloma patients (n = 225)
% of cases within subgroup CD19+CD81+ (%) CD19-CD81+ (%) CD19-CD81−(%) P-value
CD38low 67 52 67 0.09
CD138low 33 31 31 0.99
CD27+ 33 43 50 0.48
CD28+ 17 20 35 0.04
CD45+ 67 50 29   0.003
CD56+ 77 76 75 0.85
CD117+ 67 24 41   0.009
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Table 2
Cytogenetic characteristics of patients with less-differentiated (that is: CD19+CD81+) and intermediate-
differentiated (that is: CD19-CD81+) vs more-differentiated (that is: CD19-CD81−) plasma cell clones among 
newly diagnosed multiple myeloma patients (n = 169)
Genetic abnormality PCs differentiation subset P-value
CD19+ CD81+ (%) CD19-CD81+ (%) CD19-CD81− (%)
Any 25 62 72 0.07
t(4;14) 0 24 17 NS
t(11;14) 0 68 36 0.03
t(14;16) 0 0 11 NS
+1q 25 41 54 NS
del(13q) 0 49 51 NS
del(17p) 0 13 8 NS
High-risk FISH 0 23 19 NS
Abbreviation: NS, not significant.
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Table 3
Multivariate analyses including baseline disease features with univariate significant effect on PFS and/or OS 
of newly diagnosed elderly myeloma patients included in the GEM2010MAS65 trial
PFS OS
HR P HR P
Age (< 75 vs ≥ 75 years) 1.3 0.21 2.7   0.001
ISS 1.2 0.50 1.9 0.16
Interphase FISH cytogenetics (standard- vs high-risk) 1.9 0.003 2.7   0.001
PC differentiation stage 1.7 0.005 2.1   0.006
Abbreviations: FISH, Fluorescence-in situ-hybridization; High-risk FISH, t(4;14), t(14;16) and/or del(17p13); ISS, International Staging System; 
OS, overall survival; PC, plasma cell; PFS, progression-free survival.
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